BridgeBio (BBIO) Pharma announced the Company will host an investor webinar on Friday, July 11, 2025 at 8:00 am ET with Matthew Wicklund, M.D., FAAN, Professor of Neurology and Vice Chair for Research, Department of Neurology at the University of Texas Health Science Center San Antonio. Dr. Wicklund will provide an overview of limb-girdle muscular dystrophy, specifically focusing on the disease burden, standard of care and unmet needs for those with limb-girdle muscular dystrophy type 2I/R9. He serves as director for the UT Health San Antonio MDA Multidisciplinary Care Center and is a member of the Limb-girdle Muscular Dystrophy Clinical Research Network and the Neuromuscular Study Group. Dr. Wicklund has participated in over 35 multi-center clinical trials in the areas of muscular dystrophy, ALS, and myasthenia gravis and has over 200 published articles, chapters and abstracts. In addition to Dr. Wicklund, executive members of the LGMD2I/R9 program will review the progress of BBP-418 to date and discuss expectations for the Phase 3 interim analysis results expected in the second half of 2025.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio price target raised to $54 from $50 at BofA
- BridgeBio Pharma’s Promising Growth Potential Driven by Attruby and Upcoming Pivotal Readouts for Encaleret and BBP-418
- TipRanks’ ‘Perfect 10’ Picks: 2 Top-Scoring Stocks That Are Ticking Every Box
- BridgeBio Pharma Annual Meeting Approves Key Proposals
- Avidity, BridgeBio, Coty, SAGE, Alkermes: Trending by Analysts